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OBJECTIVE. Plasmatic B-type-natriuretic peptide (NT-PBNP) and C-reactive protein (CRP) have been reportedly 
elevated in stroke patients; however their clinical significance remains uncertain. The purpose of this work is to 
investigate whether elevation of these proteins at baseline predicts CT-evidence of brain edema. 
METHODS. We recruited 41 consecutive patients with stroke and determined NT-PBNP and CRP at baseline 
(within 5 hours after onset), after 48-72 hours, and at discharge. Stroke severity was measured by means of the 
NIHS scale at baseline and at discharge. We also carried out brain CT at admittance and after 48 hours. 
RESULTS. There were 29 ischemic strokes and 12 hemorrhagic strokes. Evidence of brain edema on delayed scan 
was seen in 14 patients. Baseline levels of NT-PBNP did not predict CT-evidence of edema but CRP levels did so 
significantly (0.7 mg/dl in patients without edema versus 4.7 mg in patients with edema; p=0.001). Both 
NT-PBNP and PC levels correlated poorly to NIHSS score and increased markedly from baseline to the second 
determination in patients with edema. For these patients the NT-PBNP increase was 133.6 pmol/l in comparison 
to 1.58 pmol/l in patients without edema (p=0.002). Neither CRP nor NT-PBNP baseline levels were predictive of 
dependency or death.   
CONCLUSIONS. We conclude that CRP at baseline but not NT-PBNP predicts CT evidence of brain edema in 
stroke patients. We hypothesize that NT-PBNP levels elevated in response to edema after 48 hours of admission. 
Key words: Stroke; Brain edema; C-reactive protein; B-type natriuretic peptide. 
INTRODUCTION 
Atrial natriuretic peptide (ANP) is released into 
circulation in response to atrial distention or sodium 
load. This counteracts the Renin-Angiotensin--
Aldosterone system and causes an increase in the 
glomerular filtration rate with excretion of sodium and 
water. Brain natriuretic peptide (BNP) is released from 
the ventricular myocardium in response to elevation of 
ventricular diastolic pressure [1]. BNP is known to 
correlate with the presence and severity of congestive 
heart failure [2]. Usually it is determined the 
N-terminal fragment (NT-pro-BNP) of the BNP. In the 
last years, the NT-pro-BNP levels in the serum have 
emerged as important predictor of mortality in stable 
coronary heart disease [3]. It has also bee regarded as 
predictor of mortality and cardiovascular events in 
older adults [4], as predictor of sudden death in 
patients with chronic heart failure [5], and as predictor 
of the risk of cardiovascular events and death in 
persons without heart failure [6]. BNP levels are also 
predictive of heart failure [7] and myocardial infarction 
[8] in patients with stroke or TIA. Furthermore, BNP 
levels are also predictive of ischemic stroke in patients 
with cerebrovascular disease beyond traditional risk 
factors [9]. 
   C-reactive protein is a well-known marker of 
inflammation but the role as marker of 
atherothrombosis is currently being investigated. CRP 
was also related to increased mortality and 
cardiovascular events in older adults [4], to increased 
risk of heart failure in subjects with cerebrovascular 
disease [7], and to increased risk of stroke and TIA in 
the elderly [10]. 
   ANP [11-13], BNP [13-15], and CRP [16-22] have 
been reported to be elevated in the acute phase of 
stroke but their clinical significance is mostly 
unknown. Brain edema is common in acute stroke and, 
many times, life-threatening. The reason for which 
malignant edema develops in some patients but does 
not in others is so far elusive. It becomes especially 
manifest after 48 hours from stroke onset. However on 
many occasions the edema is not seen until 48 hours or 
later from onset.   
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baseline markers of delayed brain edema that might be 
helpful to anticipate the appropriate and early 
anti-edema measures. We hypothesize that plasmatic 
BNP and CRP values in hyperacute stroke might 
predict the development of CT-based evidence of 
delayed brain edema, and that these proteins increase 
in response to edema. The second objective of the 
study is to know whether the values of these proteins 
change according to clinical outcome.  
PATIENTS AND METHODS 
In this work we enrolled 48 patients with stroke 
in a consecutive manner. Stroke was defined as rapidly 
developing symptoms and signs of focal cerebral 
dysfunction lasting more than 24 hours with no 
apparent origin other than vascular. On admission we 
carried out general medical and neurological 
examination, blood pressure measurement, 
electrocardiogram, X-ray film of the chest, and brain 
Computed Tomography. Immediately a blood sample 
was drawn to determine ultrasensitive C-reactive 
protein and the N-terminal fraction (NT-PBNP) of the 
B-type natriuretic peptide within 5 hours after stroke 
onset. Serum NT-PBNP levels were measured by 
electrochemiluminiscence immunoassay on a Modular 
Analytics E170 analyzer (Roche Diagnostics). 
Ultrasensitive C-reactive protein (CRP-U) was 
measured by quantitative immunoturbidimetric assay 
on an Architect c-8000 analyzer (Abbot Diagnostics). 
The normal NT-PBNP values in the serum for 
healthy people are below 30 pmol/l and those of CRP 
below 0.05 mg/dL. 
The stroke severity was measured by means of 
the National Institute of Health Stroke Scale (NIHSS). 
At 48 hours after admission we also carried out a new 
brain CT and determined again the CRP and NT-PBNP 
in the serum because the edema tends to be more 
evident after this elapse of time. By edema in ischemic 
stroke we mean mass-effect and sulcal effacement. For 
hemorrhagic stroke we mean the surrounding 
hypodensity of the hematoma with increased 
mass-effect in comparison to baseline scan. CT images 
were evaluated for the presence/absence of edema 
before knowing the levels of CRP and NT-PBNP.  
  At discharge we performed another 
determination of CRP and NT-PBNP in the serum, as 
well as new NIHS scale and the modified Rankin scale 
for assessing independence. 
  For statistical analysis we divided the patients 
into two groups: those who developed edema at 48 
hours and those who did not. Comparisons were made 
with either t-Test or Mann-Whitney U-test in 
accordance with the presence/absence of normality in 
the distribution of the variables. We also analyzed 
correlation between stroke severity and the values of 
CRP and NT-PBNP. The predictive values were 
analyzed by means of the ROC curves. A model of 
logistic regression was constructed to predict edema so 
as to control for potential confounders such as age, sex, 
atrial fibrillation, hypertension, diabetes, and 
hyperlipidemia. Operations were made with the SPSS 
software, version 10 (Chicago, IL). 
 This study was made with the informed consent 
of patients and/or relatives, and the authorization of 
the local review board as well. 
RESULTS 
 Among the 48 patients recruited 4 were excluded 
because of congestive heart failure (signs of 
pulmonary edema on Rx film of the chest and/or 
reduced ventricular function on echocardiography) 
and 3 because of early death from ischemic stroke. The 
cause of early death was brain herniation in two 
patients, and heart failure in the other. The mean age 
of the patients excluded was 84.5 years; two were 
women and two were man. The four excluded patients 
showed very high levels of NT-PBNP (> 400 pmol/L) 
as it is expected in patients with heart failure. The 
remaining 41patients underwent the complete protocol 
of the study. The mean age of the 41 patients was 78.3 
years (range: 54-91). There were 26 men and 15 
women. None of the patients included had history of 
congestive heart failure nor underwent thrombolysis. 
We neither saw patients with renal failure on the basis 
of plasmatic creatinine levels. In table 1 are reported 
the main baseline characteristics and risk factors. 
Table 1. Main baseline characteristics and risk factors. N=41 
Mean age: 78.32 (SD: 6.77); range: 54-91 
Sex: 26 male (634%) and 15 female. 
Mean temperature on admission : 36.6 0C (SD:0.4) 
Mean systolic blood pressure on admission: 164.49 (25.36); range: 
107-220 mm Hg 
History of hypertension: 21 (51.2%). 
Atrial fibrillation: 4 (9.75%). 
Diabetes mellitus: 9 (22%) 
Hyperlipidemia: 7 (17%) 
Trasient ischemic attack : 9 (21.9%) 
Coronary Heart Disease : 4 (9.75%) 
Tobacco habit: 3 (7.3%) 
Obesity: 4 (9.75%) 
 
The type of stroke was ischemic in 29 patients and 
hemorrhagic of hypertensive cause in 12. Among 
ischemic strokes 6 were cardioembolic, 7 were lacunar, 
and the remainder (16) were ischemic 
non-cardioembolic (11 atherosclerotic and 5 of 
undetermined cause). The location of stroke was the 
anterior circulation in 30 patients and the posterior 
circulation in 11. The hemorrhagic stroke location was 
as follows: basal ganglia in 8, lobar in 2, thalamic in 
one patient, and cerebellar in another one. Int. J. Med. Sci. 2008, 5 
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On delayed CT 14 patients showed evidence of 
brain edema and 27 did not. The mean age for patients 
with edema was 80.29 years (SD: 4.16), and 77.3 (SD: 
7.67) for those without edema (difference not 
significant). Among patients with edema 3 were 
female and 11 male. History of hypertension was 
positive in 5 patients (35.7%) who showed edema and 
in 16 (59.2%) of those without edema. The mean 
systolic/diastolic blood pressure at baseline for 
patients with edema was 166/80 mm Hg in 
comparison to 163/77 in those without edema. After 48 
hours of stroke onset the blood pressure only elevated 
in 3 patients with edema (from 130/75 to 160/92; from 
155/85 to 170/95; and from 165/90 to 188/100); in the 
remainder it was similar as at baseline. The mean 
NIHSS score on admission was 7.5 (SD: 6.18) and at 
discharge it was 5.94 (SD: 6.54). For patients with 
ischemic stroke the baseline NIHSS was 7.6 (SD: 5.4) 
and 7.3 (SD: 5.1) for those with hemorrhage. The mean 
NIHSS score for patients with edema was 11.77 (SD: 
6.5) and for those without edema it was 5.5 (SD: 4.2), 
which was significant on t-test (p=0.007).  
 The mean length of stay in hospital was 8.2 days 
(range: 3-30 days), and 5 patients died from stroke 
after having obtained the second blood sample for 
determinations of the proteins. The mean Rankin score 
at discharge was 2.14 (SD: 1.83) with 22 patients being 
independent. None of the patients included in the 
study had overt evidence of infection on admission on 
the basis of standard blood and urine tests, X-film of 
the chest and temperature controls. 
  In table 2 are presented the values of CRP and 
NT-PBNP of three determinations for all of the patients 
of the study. These values were increased in the three 
determinations in comparison to those of healthy 
people with the highest peak in the second 
determination. In table 3 are reported separately the 
same values for patients with edema and for those 
without edema. The 4 patients excluded because of 
congestive heart failure had very high levels of 
NT-PBNP (>400 pmol/l) and normal CRP values on 
admission. 
 
Table 2. Mean values of CRP and NT-PBNP of the 41 patients 
VALUES MEAN  SD RANGE 
CRP-Baseline 2.08 4.36 0.03-20.7  mg/dl 
CRP-48 hours  3.94  6.4  0.09-26.13 
CRP-Discharge 3.44  5  0.04-24.8 
 
NT-PBNP-baseline 103.1  169.7 2.8-672  pmol/l 
NT-PBNP-48 hours  144.22  187.3  1.6-798.3 
NT-PBNP-Discharge 111.8  171.55  1.58-736 
 
Table 3. Values of CRP and NT-PBNP for patients with and 
without brain edema. IQ range means 25-75% interquartile 
range. 
VALUES EDEMA-  YES 
(14) 
EDEMA- NO 
(27) 
P 
values 
CRP-baseline  Mean: 4.7 (6.76) 
mg/dL 
Median: 1.61 
mg/dL 
IQ range : 
0.61-6.4 
Mean: 0.78 (0.94) 
mg/dL 
Median: 0.37 
mg/dL 
IQ range : 
0.19-1.16 
0.001 
CRP-48 hours  Mean: 8.01 (8.4) 
mg/dL 
Median: 5.39 
IQ range: 
1.73-12.47 
Mean: 1.76 (3.5) 
mg/dL 
Median: 0.53 
IQ range: 
0.28-1.82 
0.0001 
CRP-Discharge  Mean: 7.25 (7.3) 
mg/dL 
Median: 5.94 
IQ range: 
1.64-10.1 
Mean: 1.92 (2.67) 
mg/dL 
Median: 0.47 
 IQ range: 
0.27-2.78 
0.003 
 
NT-PBNP-Baseline Mean:  76.88 
(86.7) pmol/L 
Median: 36.6 
IQ range: 
20.95-99.32 
Mean: 116.72 
(201.07) 
Median: 33.85 
IQ range: 
16.67-98.55 
0.2 NS 
NT-48 hours  Mean: 191.45 
(201.18) 
Median: 141.55 
 IQ range: 
60.55-274.15 
pmol/L 
Mean: 118.8 
(178.36) 
Median: 31.5 
 IQ range: 
11.95-158 
pmol/L 
0.26 
NS 
NT-Discharge Mean:  111.65 
(84.79) 
Mean: 111.86 
(197.47) 
0.9 NS 
 
On admission the mean value of CRP for patients 
with edema was 4.7 mg/dl in comparison to 0.78 for 
patients without edema (p=0.001on MW-U-test), see 
figure 1. The difference remained significant after 
controlling for hypertension, atrial fibrillation, 
hyperlipidemia, diabetes and history of stroke. CRP 
values remained elevated after 48 hours and at 
discharge with significant higher levels in patients 
with edema. The ROC curve of the initial CRP values 
was predictive of edema with an area under the curve 
of 0.8 (95% CI: 0.64-0.95), see figure 2. 
As it was expected the patients with lacunar 
infarctions had lower CRP levels (mean: 0.22 mg/dl) 
than those with non-lacunar stroke. All but one patient 
had the CRP level below 1 mg/dl. We neither saw 
differences in the baseline levels of CRP between the 
cardioembolic and atherosclerotic strokes (2.2 and 1.93 
mg/dL respectively). In a model of logistic regression 
only baseline CRP level and systolic blood pressure 
were related to edema significantly (see table 4). 
Variables such as age, sex, atrial fibrillation, history of 
hypertension, and diabetes were excluded from the 
equation by the model. 
The NT-PBNP values were also elevated in the 
three determinations but the between-group 
differences were not significant. However after 48 
hours the values of NT-PBNP increased significantly 
more in patients with edema (133.6 pmol/l) in Int. J. Med. Sci. 2008, 5 
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comparison to those without edema (1.58 pmol/l); 
p=0.002 on t-test. See figure 3. 
In table 5 are presented the different values for 
ischemic and hemorrhagic stroke without significant 
differences. Ischemic strokes showed higher values of 
NT-PBNP and lower values of CRP than hemorrhagic 
strokes without statistical significance.  
 
FIGURE 1. Graphic showing the mean values of plasmatic 
C-reactive protein in three determinations. 
 
 
FIGURE 2. ROC curve of the CRP baseline values. Area under 
the curve: 0.8 (95% CI: 0.64-0.95). 
 
 
FIGURE 3. Graphic showing the mean values of NT-PBNP in 
three determinations. Vertical axis represents the values in 
pmol/l. 
Table 4. Model of logistic regression. Dependent variable was 
brain edema. 
Independent 
variable 
B T  Exp  (B)  Significance 
Systolic 
blood press. 
0.065 4  1.06 0.04 
CRP at 
baseline 
1.66 4.5 5.27 0.03 
Constant -11.29  4.3  0.00  0.03 
Variables not 
in the 
equation 
     
SEX -0.16  0.02  0.84 0.8 
AGE 0.082  1.04  1.08  0.3 
History of 
Hypertension 
-1.19 1.75  0.0  0.18 
Diabetes 
mellitus 
-0.64 0.44 0.52  0.5 
Atrial 
fibrillation 
6.1 0.03  0.002 0.8 
 
 
 
Table 5. CRP and NT-PBNP values for ischemic and 
hemorrhagic stroke. 
VALUES ISCHEMIC 
STROKE 
(n=29) 
HEMORRHAGIC 
STROKE (n=12) 
P 
VALUES 
CRP-Baseline 1.16  (1.71) 4.3  (7.36)  0.17 
CRP-48 hours  2.56 (3.73)  7.16 (9.8)  0.14 
CRP-Discharge  2.51 (2.76)  5.78 (8.15)  0.24  
      
NT-PBNP-Baseline 120.8 
(194.47) 
61.61 (81.3)  0.09 
NT-PBNP-48 hours  162.19 
(213.16) 
102.3 (101.17)  0.23 
NT-PBNP-Discharge 128.92 
(198.25) 
69 (59.39)  0.18 
 
We did not find relationship between systolic 
blood pressure on admission and values of CRP and 
NT-PBNP. We neither found relationship between the 
baseline values of CRP and NT-PBNP and dependence 
at discharge or death. The mean baseline CRP level for 
independent patients at discharge (Rankin 0, 1, or 2) 
was 1.64 (SD: 4.4) in comparison to 2.78 (SD: 4.5) in 
those dependent (Rankin 3,4, or 5), which was not 
significant. The levels of NT-PBNP were neither 
related to age (r=0.23) or sex. Although women had 
higher mean baseline levels of NT-PBNP than men 
(117.75 pmol/L and 95.21 respectively), the difference 
was not statistically significant (p=.69). 
Figure 4 represents and example of ischemic 
stroke and hemorrhagic stroke on baseline and 
delayed CT with edema developing after 48 hours. Int. J. Med. Sci. 2008, 5 
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FIGURE 4. A. Ischemic stroke presenting with left 
hemiparesis. Normal CT on admission. CRP level: 6.9 m/dL; 
NT-PBNP level: 21pmol/L. B. CT scan after 48hours. Large 
infarction in the MCA territory showing mass-effect. CRP level: 
7.9 mg/dL; NT-PBNP level: 139 pmol/L. 
 
 
 
FIGURE 5. A. CT on admission. Hemorrhagic stroke 
presenting with headache and left hemiplegia. CRP level: 3.23 
mg/dL. NT-PBNP level: 66.3 pmol/L. B. CT scan after 48 hours 
in the same patient. See the surrounding hypoatenuation of the 
hematoma with increased mass-effect. CRP level: 22.6. 
NT-PBNP level: 197 pmol/L. 
DISCUSSION 
The role of CRP in inflammation and 
atherosclerosis has attracted the attention of many 
researchers but it is not clear whether CRP is only a 
marker or a causal factor [23]. This protein has been 
widely studied in the acute phase of ischemic stroke. 
Compared with controls CRP levels in the serum were 
higher than healthy controls in all stroke subtypes, in 
the acute phase and after 3-month follow-up [16]. The 
CRP levels correlated positively with the size of the 
infarct and stroke severity [17,18]. Furthermore CRP 
elevation in ischemic stroke indicates a worse 
prognosis, as it has been associated with higher 
in-hospital mortality  [9,20], higher mortality at 6 
months  [21], and more disability  [22]. From the 
Perindopril Protection against Recurrent Stroke a 
case-control study showed that NT-PBNP levels but 
not CRP predicted stroke recurrence [9]. In this study 
we did not find prognostic significance of either CRP 
or NT-PBNP but we found relationship between the 
levels of these proteins and the size of the stroke lesion 
as edema tends to appear in large lesions. The lack of 
prognostic significance may be caused by the small 
sample size. Initially, one can speculate that the 
baseline CRP levels are related to the degree of carotid 
arteriosclerosis but two facts are against this 
hypothesis: the CRP levels were higher in hemorrhagic 
strokes, and that we found no differences of CRP levels 
between cardioembolic and atherosclerotic strokes. 
The significance of NT-PBNP elevation in the 
acute phase of stroke is mostly unknown. In 86 
consecutive patients with ischemic stroke the 
NT-PBNP levels were related to unfavorable outcome 
included death of any cause [24]. NT-PBNP levels in 
250 patients at day 2 after ischemic stroke onset were 
predictive of 6-month mortality [25]. However another 
studies including 174 and 30 patients respectively with 
ischemic stroke concluded that NT-PBNP levels did 
not influence the clinical outcome  [14,15]. The 
relationship between NT-PBNP levels and brain 
edema in the acute phase of stroke has been little 
investigated. Elevations of NT-PBNP were associated 
with hyponatremia and natriuresis in subarachnoid 
hemorrhage  [26] as well as to hyponatremia and 
delayed vasospasm-related ischemic deficits [27]. Focal 
brain edema was related with elevations of ANP and 
BNP in 8 patients with subarachnoid hemorrhage [28]. 
In rodent model of subarachnoid hemorrhage the 
intraventricular administration of ANP reduced the 
sodium and water accumulation, as well as brain 
edema [29]. In rats with provoked-hemorrhagic stroke 
the intraperitoneal administration of ANP reduced 
water, sodium and edema 24 hours after the injury but 
mannitol did not so, which suggests that ANP could be 
used to treat brain edema [30]. The role of ANP in 
regulating blood flow in the infarcted area was studied 
in stroke patients and a statistically significant increase 
in the number of ANP-immunoreactive astrocytes was 
found in the white matter surrounding the infarction 
area [31].  
We observed elevation of NT-PBNP in relation to 
brain edema in ischemic and hemorrhagic strokes as 
these levels showed the maximum peak after 48 hours 
from stroke onset. It is not likely that these elevations 
related with blood pressure elevations as it only 
occurred in 3 patients with edema. Our findings and 
those of the previous studies suggest that natriuretic 
peptides are produced in response to edema so as to 
reduce it. Whether or not the treatment with BNP may 
constitute an alternative of treatment in 
stroke-induced brain edema remains to be elucidated. 
The lack of efficacious treatment so far for 
stroke-induced brain edema makes our hypothesis Int. J. Med. Sci. 2008, 5 
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worthy of consideration. 
  The most important shortcoming of our study 
was that edema was evaluated only with CT and, 
therefore, we focused only on severe edema. The 
practice of Diffusion weighted MRI would have added 
important information but unfortunately this 
technique was unavailable for us. 
  In conclusion, our work adds something new to 
the understanding of the elevation of CRP and 
NT-PBNP in the acute phase of stroke. both CRP and 
NT-PBNP are markers of brain edema in stroke at 
baseline and after 48 hours respectively. Given that 
brain edema may be a life-threatening condition, 
anti-edema measures could be anticipated in 
hyperacute stroke in patients with high baseline levels 
of ultrasensitive C-reactive protein. Owing to the small 
sample size of our study these results need to be 
confirmed in larger samples of stroke patients. 
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